lasmiditan + probe drug cocktail

**Lasmiditan + probe drug cocktail** is a combination used primarily in clinical pharmacokinetic studies to assess potential drug-drug interactions. Lasmiditan is a **selective serotonin 5-HT1F receptor agonist** (ditan), developed for the acute treatment of migraine with or without aura in adults. It is administered as lasmiditan hemisuccinate, typically in oral tablet form. The probe drug cocktail refers to the co-administration of lasmiditan with probe substrates (such as dabigatran etexilate and rosuvastatin) to evaluate the effect of lasmiditan on pharmacokinetics and transporter activity. Lasmiditan inhibits efflux transporters, specifically **P-glycoprotein (P-gp)** and **breast cancer resistance protein (BCRP)**. These probe drugs (dabigatran for P-gp and rosuvastatin for BCRP) are standard tools in clinical DDI (drug-drug interaction) studies[2].

Other names

lasmiditan hemisuccinate